Key Quantitative Figures - Standalone (Q1 FY27)

Income Statement (₹ millions):

  • Revenue from operations: ₹3,722.84 (vs. ₹3,232.69 in Q1 FY26)
  • Other income: ₹51.86 (vs. ₹27.79 in Q1 FY26)
  • Total Income: ₹3,774.70 (vs. ₹3,260.48 in Q1 FY26)
  • Cost of materials consumed: ₹684.74
  • Employee benefits expense: ₹852.43
  • Finance costs: ₹47.53
  • Depreciation and amortization: ₹278.06
  • Other expenses: ₹1,180.30
  • Total Expenses: ₹3,110.94
  • Profit before tax: ₹663.76 (vs. ₹473.84 in Q1 FY26)
  • Tax expense: ₹157.22
  • Profit from continuing operations: ₹506.54 (vs. ₹353.59 in Q1 FY26)
  • Loss from discontinued operations: ₹(0.71)
  • Total profit for period: ₹505.83 (vs. ₹355.82 in Q1 FY26)

Earnings Per Share (Face value ₹2):

  • Basic EPS (continuing): ₹2.44 (vs. ₹1.72 in Q1 FY26)
  • Diluted EPS (continuing): ₹2.44 (vs. ₹1.72 in Q1 FY26)
  • Basic EPS (total): ₹2.44 (vs. ₹1.73 in Q1 FY26)
  • Diluted EPS (total): ₹2.44 (vs. ₹1.72 in Q1 FY26)

Capital Structure:

  • Paid-up equity share capital: ₹414.67 million

Key Quantitative Figures - Consolidated (Q1 FY27)

Income Statement (₹ millions):

  • Revenue from operations: ₹4,502.15 (vs. ₹3,860.63 in Q1 FY26)
  • Other income: ₹51.02 (vs. ₹75.16 in Q1 FY26)
  • Total Income: ₹4,553.17 (vs. ₹3,935.79 in Q1 FY26)
  • Profit before tax: ₹777.12 (vs. ₹612.30 in Q1 FY26)
  • Tax expense: ₹208.29
  • Profit for period: ₹568.83 (vs. ₹452.45 in Q1 FY26)
  • Total comprehensive income: ₹597.07
  • Profit attributable to owners: ₹566.67

Earnings Per Share (Face value ₹2):

  • Basic EPS: ₹2.73 (vs. ₹2.17 in Q1 FY26)
  • Diluted EPS: ₹2.73 (vs. ₹2.17 in Q1 FY26)

Capital Structure:

  • Paid-up equity share capital: ₹414.67 million
  • Other equity: ₹14,716.95 million

Operational Highlights

Business Transfer Delay:

The sale and transfer of External Quality Assessment Services Business to Metropolis Quality Solutions Private Limited (wholly owned subsidiary), originally scheduled to be completed within 6 months of the Business Transfer Agreement dated February 04, 2026, is now expected to take an additional 2 months (total 8 months).

Business Acquisitions (Completed in FY26):

1. Dapic Metropolis Healthcare Private Limited acquired business of Dr. Ahujas' Pathology & Imaging Centre for ₹346.10 million (consummated May 23, 2025)

2. Scientific Metropolis Pathology Private Limited acquired business of Dr. Ashok Kumar Sharma's Scientific Pathology for ₹645.00 million (consummated June 16, 2025). Dr. Ashok Kumar Sharma acquired 10% equity stake, making it a subsidiary rather than wholly owned.

3. Company acquired pathology laboratories from Dr. RS Patil's Ambika Pathology Laboratory for ₹170.00 million (completed September 18, 2025)

Employee Stock Grants:

During the quarter, the Nomination and Remuneration Committee approved:

  • 14,236 Restricted Stock Units (RSU) under Metropolis Restrictive Stock Unit Plan - 2025
  • 212,345 Employees Stock Options under Metropolis Employees Stock Option Plan - 2025
  • Additionally, 4,200 RSUs were allotted under Metropolis Restrictive Stock Unit Plan - 2020

Regulatory and Accounting Notes

Presentation Change:

The company changed presentation of financial information from ₹ in Lakhs to ₹ in Millions effective Q1 FY27. Comparative figures have been restated accordingly.

Segment Information:

Based on nature of business and products/services, there is only one reportable segment: Pathology service.

Labour Code Impact:

The Government of India notified four Labour Codes on November 21, 2025. The company restructured compensation of employees effective April 1, 2026, and presented the incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" in Q4 FY26 results.

Bonus Issue:

The company issued and allotted 155,495,826 bonus equity shares in 3:1 ratio (three new shares for every one existing share) approved by board on February 4, 2026, and shareholders on March 8, 2026.

Meeting Details

Board meeting commenced at 02:00 p.m. (IST) and concluded at 05:20 p.m. (IST) on August 04, 2026.

Auditor Review

Both standalone and consolidated financial results were reviewed by statutory auditors BSR & Co. LLP who issued unmodified review reports.

Subsidiaries Included in Consolidation

The consolidated results include numerous subsidiaries across India, Mauritius, Sri Lanka, Tanzania, Ghana, Kenya, and Uganda, including wholly owned subsidiaries and partially owned entities.

Availability of Results

The financial results are available on the company's website at www.metropolisindia.com and on stock exchange websites.